MDCM
MYGN icon

Morgan Dempsey Capital Management’s Myriad Genetics MYGN Stock Holding History

Morgan Dempsey Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-844
Closed -$32K – 213
2016
Q1 		$32K Sell
844
-44
-5% -$1.66K 0.01% 139
2015
Q4 		$38K Hold
888
– – 0.01% 150
2015
Q3 		$33K Buy
+888
New +$31.5K 0.01% 149

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Morgan Dempsey Capital Management's MYGN Position: Q2 2016 in Review

Morgan Dempsey Capital Management sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 844 shares — an estimated $32K sold.

Morgan Dempsey Capital Management first reported a position in MYGN in Q3 2015 and held it in 3 quarters. The position peaked at $38K in Q4 2015. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

  • Morgan Dempsey Capital Management reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
  • Morgan Dempsey Capital Management sold 844 Myriad Genetics shares in Q2 2016, an estimated $32K.
  • Morgan Dempsey Capital Management first reported a position in Myriad Genetics in Q3 2015 and held it in 3 quarters.
  • Morgan Dempsey Capital Management's Myriad Genetics position peaked at $38K in Q4 2015.
  • 252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Morgan Dempsey Capital Management's 13F filing for Q2 2016, filed 28 Jul 2016.